Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 2;77(5):706–713. doi: 10.1136/annrheumdis-2017-212504

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

Association of LLDAS with PROs for pooled patients with active SLE treated with placebo or anifrolumab. (A) Mean PaGA scores at baseline and Week 52 by LLDAS attainment at Week 52. (B) Mean LupusQOL domain scores at Week 52 by LLDAS attainment at Week 52. The nominal p-values and delta for comparing the difference in mean scores between patients in LLDAS and those who did not attain LLDAS at Week 52 were based on an ANCOVA test adjusted for treatment, randomisation stratification factors and respective baseline domain scores. Nominal p-values for comparing baseline with Week 52 PaGA scores were based on a Wilcoxon signed rank test. ANCOVA, analysis of covariance; LLDAS, Lupus Low Disease Activity State; PaGA, Patient ’s Global Assessment; PROs, patient-reported outcome; QOL, Quality of Life.